Names Under Consideration
USAN Council's statement on the use of USAN as domain names:
A name published by the United States Adopted Names (USAN) Program in the USP Dictionary of USAN and International Nonproprietary Names, and on the United States Adopted Names Web site, shall be the effective equivalent of an intellectual property right on the part of the relevant entities.
Comments or protests should be addressed to Stephanie Shubat, USAN Program Director, American Medical Association, 515 North State Street, Chicago, Illinois 60654, or sent via email to USAN@ama-assn.org.
The following list of names for the drugs described are "under consideration" by the USAN Council:
|edabrutinib||hematological malignancies and autoimmune diseases|
|fosabenticorat||rheumatoid arthritis and potentially other inflammation diseases|
|pralmotinib||treatment of mesothelioma and ovarian tumors|
|ramabecestat||treatment of Alzheimer's disease|
|spebrutinib||hematological malignancies and autoimmune diseases|
|laziofolastat I 131||diagnostic agent, prostate cancer|
|beclabuvir||treatment of hepatitis C|
|cabtegravir||treatment of HIV Infection|
|latiglutenase||treatment of celiac disease|